2026 ICD-10-CM Diagnosis Code T47.5X5SAdverse effect of digestants, sequela
T47.5X5S is a billable ICD-10-CM diagnosis code for adverse effect of digestants, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T47.5X5S.
Present on Admission (POA)Billing
T47.5X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Adverse reaction to bile acid and/or bile acid derivative
- Adverse reaction to chenodeoxycholic acid and/or ursodeoxycholic acid
- Adverse reaction to digestant
- Adverse reaction to lipotropic drugs
- Adverse reaction to oil
- Adverse reaction to pancreatin
- Adverse reaction to papain
- Adverse reaction to pepsin
- Chenodeoxycholic acid adverse reaction
- Dehydrocholic acid adverse reaction
- Peppermint oil adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system (T47). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Betaine
a naturally occurring compound that has been of interest for its role in osmoregulation. as a drug, betaine hydrochloride has been used as a source of hydrochloric acid in the treatment of hypochlorhydria. betaine has also been used in the treatment of liver disorders, for hyperkalemia, for homocystinuria, and for gastrointestinal disturbances. (from martindale, the extra pharmacopoeia, 30th ed, p1341)Betaine-Aldehyde Dehydrogenase
an nad+ dependent enzyme that catalyzes the oxidation of betain aldehyde to betaine.Betaine-Homocysteine S-Methyltransferase
a zinc metalloenzyme that catalyzes the transfer of a methyl group from betaine to homocysteine to produce dimethylglycine and methionine, respectively. this enzyme is a member of a family of zinc-dependent methyltransferases that use thiols or selenols as methyl acceptors.Chenodeoxycholic Acid
a bile acid, usually conjugated with either glycine or taurine. it acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. it is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.Cholic Acid
a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. it facilitates fat absorption and cholesterol excretion.Cholic Acids
the 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholanic acid family of bile acids in man, usually conjugated with glycine or taurine. they act as detergents to solubilize fats for intestinal absorption, are reabsorbed by the small intestine, and are used as cholagogues and choleretics.Citric Acid
a key intermediate in metabolism. it is an acid compound found in citrus fruits. the salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.Citric Acid Cycle
a series of oxidative reactions in the breakdown of acetyl units derived from glucose; fatty acids; or amino acids by means of tricarboxylic acid intermediates. the end products are carbon dioxide, water, and energy in the form of phosphate bonds.Dehydrocholic Acid
a semisynthetic bile acid made from cholic acid. it is used as a cholagogue, hydrocholeretic, diuretic, and as a diagnostic aid.Glutamate Decarboxylase
a pyridoxal-phosphate protein that catalyzes the alpha-decarboxylation of l-glutamic acid to form gamma-aminobutyric acid and carbon dioxide. the enzyme is found in bacteria and in invertebrate and vertebrate nervous systems. it is the rate-limiting enzyme in determining gamma-aminobutyric acid levels in normal nervous tissues. the brain enzyme also acts on l-cysteate, l-cysteine sulfinate, and l-aspartate. ec 4.1.1.15.Glutamates
derivatives of glutamic acid. included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure.Glutamic Acid
a non-essential amino acid naturally occurring in the l-form. glutamic acid is the most common excitatory neurotransmitter in the central nervous system.Plasminogen
precursor of plasmin (fibrinolysin). it is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. it is used in wound debriding and has been investigated as a thrombolytic agent.RNA, Transfer, Glu
a transfer rna which is specific for carrying glutamic acid to sites on the ribosomes in preparation for protein synthesis.Pancreatin
a mammalian pancreatic extract composed of enzymes with protease, amylase and lipase activities. it is used as a digestant in pancreatic malfunction.Pancrelipase
a preparation of hog pancreatic enzymes standardized for lipase content.Coronavirus Papain-Like Proteases
papain-like proteases that occur in species of coronaviridae. some species have more than one papain-like protease gene.Papain
a proteolytic enzyme obtained from carica papaya. it is also the name used for a purified mixture of papain and chymopapain that is used as a topical enzymatic debriding agent. ec 3.4.22.2.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T47.5X5S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T47.5X5SOverview
Is T47.5X5S (Adverse effect of digestants) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of digestants, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T47.5X5S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of digestants itself has resolved, not the original event.
What MS-DRG does T47.5X5S group to?
On inpatient claims, adverse effect of digestants, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T47.5X5S be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of digestants, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is T47.5X5S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of digestants, sequela on inpatient claims.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
